This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.
The analyst estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM.
With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market.
The analyst anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033
The analyst estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM.
With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market.
The analyst anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033
Scope
- Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Parkinson’s Disease: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merz Pharmaceuticals LLC
- NeuroDerm Ltd
- USB Corp
- Newron
- Italfarmaco SpA
- Kyowa Kirin Co Ltd
- Acadia Pharmaceuticals Inc
- Ono Pharmaceutical Co Ltd
- Sumitomo Pharma Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Novartis AG
- Eisai Co Ltd
- Acorda Therapeutics Inc
- Stada Arzneimittel AG
- Meiji Co Ltd
- Amneal Pharmaceuticals Inc
- Alliance Pharma Plc
- Britannia Pharmaceuticals Ltd
- Annovis Bio Inc
- US WorldMeds LLC
- Hisamitsu Pharmaceutical Co Inc
- Lundbeck LLC
- Viatris
- Supernus Pharmaceuticals Inc
- AbbVie Inc
- Prothena Corp Plc
- Takeda (Pty) Ltd
- Organon
- Pharma Two B Ltd
- Anavex Life Sciences Corp
- Sunovion Pharmaceuticals Asia Pacific Pte Ltd
- Meiji Seika Pharma Co Ltd
- Alkahest Inc
- Teva LLC
- Glaxo Smith Kline (GSK)
- HLS Therapeutics Inc
- Roche
- ADAMAS
- IRLAB Therapeutics AB
- Neuraly Inc
- Taiyo Pharma Co Ltd
- PureIMS BV
- Alora Pharmaceuticals LLC
- PharmaTher Holdings Ltd
